NMPA approves IND for HLX48 clinical trial in patients with advanced solid tumors
Shanghai Henlius Biotech, Inc. (2696.HK) announced that its independently developed c-Met/EGFR bispecific antibody–drug conjugate (ADC), HLX48 for injection, has been approved by the National Medical Products Administration (NMPA), for the treatment of advanced and metastatic solid tumors. Recently, it has received approval from the Human Research Ethics Committee (HREC) in Australia and been acknowledged by the Therapeutic Goods Administration (TGA). To accelerate the evaluation of HLX48’s preliminary efficacy and safety in humans, the company plans to initiate multi-regional clinical trials (MRCT) simultaneously in China, Australia, and other regions to evaluate HLX48’s safety, tolerability, and preliminary efficacy in patients with advanced solid tumors.
Share:
More News
Taiho Oncology, Inc. completed a New Drug Application (NDA) submission to the U.S. Food and Drug Administration (FDA) for zipalertinib in combination with platinum-based chemotherapy for the treatment of patients with previously untreated, locally advanced or metastatic non-small cell lung cancer (NSCLC) harboring epidermal growth factor receptor (EGFR) exon 20
“This collaboration reflects our conviction that atebimetinib has the potential to become an essential backbone therapy in a broad range of combinations across MAPK-driven cancers,” said Ben Zeskind, Immuneering CEO and co-founder. “Atebimetinib’s unique tolerability profile and broad activity make it well suited to combine with a wide range of
“These final updated results provide continued evidence of the potential for γδ T cell therapies to drive activity and improve outcomes for patients,” said William Ho, CEO and co-founder of IN8bio. “The clinical outcomes and observed activity are supported by our correlative analysis, including histopathology, demonstrating the expansion and persistence
“Patients with RAS-mutated mCRC have no first-line therapies specifically approved for their disease, and Fast Track designation reflects the potential of onvansertib to address this serious unmet need,” said Mani Mohindru, PhD, President and Chief Executive Officer of Cardiff Oncology. “Our randomized Phase 2 data give us confidence that onvansertib